Trial Profile
An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Gadoteridol
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Adverse reactions; First in man
- 02 Nov 2023 Results published in the Neuro-Oncology.
- 06 Jul 2023 According to a Biodexa Pharmaceuticals Media Release, the company has announced the publication of the results of an investigator-initiated Phase I study PNOC015 (also known as MTD-201) of MTX110 in the treatment of pediatric patients with DMG (formerly known as Diffuse Intrinsic Pontine Glioma, or DIPG) in the Journal of Neuro-Oncology.
- 08 Apr 2021 Status changed from active, no longer recruiting to completed.